- Consistent A1C results: 17.5% of patients on Lantus® and 10.1% on those on OADs achieved A1C ≤ 6.5% at 2 consecutive visits (P=0.032)4
- Efficacy with once-daily dosing5
- Rates of severe and overall hypoglycemia were similar between Lantus® + OADs vs OAD adjustment alone (0.5% for both groups, and 48.5% vs 42.2%, respectively)4
A 24-week study of patients with T2DM randomized to start Lantus® with self-titration (n=206) or conventional therapy with physician adjustment of OADs (n=199). Patients had to be taking 0 to 2 OADs, with at least one taken at or below half maximal dose at study start. Patients could not have any substantial change in oral dose for at least 3 months before randomization.
A randomized study of patients with IFG and/or IGT or early T2DM and established CV disease or CV risk at baseline. Patients received either Lantus® (n=6264) titrated to a target FPG of ≤ 95 mg/dL or standard care (n=6273). Standard care patients remained on their original treatment, if applicable, at randomization. Additional agents could be added as needed per the discretion of the investigator. Median follow-up: 6.2 years.2,6
- No statistically significant difference between Lantus® and standard care in the incidence of CV events. P=NS2,7
- Demonstrated long-term CV safety data–including CV death, nonfatal MI, nonfatal stroke, revascularization, or hospitalization for heart failure2.
- Incidence of severe hypoglycemia (5.6% Lantus® and 1.8% Standard Care)2,7